Reuters logo
BRIEF-FDA grants fast track status to Astellas for acute myeloid leukemia drug
October 11, 2017 / 1:06 AM / 12 days ago

BRIEF-FDA grants fast track status to Astellas for acute myeloid leukemia drug

Oct 10 (Reuters) - Astellas Pharma Inc-

* U.S. FDA grants fast track designation to Astellas for development of gilteritinib in relapsed or refractory acute myeloid leukemia Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below